A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Key Inclusion Criteria:

Unresectable and/or metastatic solid tumors that have received standard-of-care (SOC) therapies previously and have no other SOC options available
Confirmed HLA-A*02:01 haplotype
Confirmed MAGE-A4 expression
Radiologically measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Life expectancy of >/=12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Absence of rapid disease progression, threat to vital organs or non-irradiated lesions >2 cm in diameter at critical sites
No significant ongoing toxicity from prior anticancer treatment
Adequate hematological function
Adequate liver function
Adequate renal function
If applicable, willingness to use contraceptive measures.

Key Exclusion Criteria:

History or clinical evidence of CNS primary tumors or metastases
Another invasive malignancy in the last 2 years
Uncontrolled hypertension
Significant cardiovascular disease
Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic or other infection
Current or past history of CNS disease
Dementia or altered mental status that would prohibit informed consent
Active auto-immune disease or flare within 6 months prior to start of study treatment
Expected need for regular immunosuppressive therapy or with systemic corticosteroids
Insufficient washout from prior anti-cancer therapy
Prior treatment with a bispecific T-cell engaging or adoptive cell therapy.